| Cara Therapeutics (CARA) | |||
|---|---|---|---|
| 11.5 0.23 (2.04%) | 08-08 16:00 | ||
| Open: | 11.03 | Pre. Close: | 11.27 |
| High: | 11.65 | Low: | 10.9239 |
| Volume: | 622,760 | Market Cap: | 616M |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 11.657 - 11.691 | 11.691 - 11.73 |
| Low: | 10.819 - 10.86 | 10.86 - 10.905 |
| Close: | 11.426 - 11.489 | 11.489 - 11.561 |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 13.61  One year: 15.89 |
| Support: | Support1: 9.47 Support2: 8.13 |
| Resistance: | Resistance1: 11.65 Resistance2: 13.61 |
| Pivot: | 9.58 |
| Moving Averages: | MA(5): 10.24 MA(20): 9.52 MA(100): 9.87  MA(250): 11.88 |
| MACD: | MACD(12,26): 0.34 Signal(12,26,9): 0.12 |
| %K %D: | %K(14,3): 98.16 %D(3): 81.41 |
| RSI: | RSI(14): 70.15 |
| 52-Week: | High: 18.93 Low: 7.4 Change(%): -8.3 |
| Average Vol(K): | 3-Month: 484 10-Days: 555 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CARA ] has closed above the upper band by 4.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 48.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 53.59 |
| Shares Float (M) | 44.97 |
| % Held by Insiders | 16.24 |
| % Held by Institutions | 61.49 |
| Shares Short (K) | 7030 |
| Shares Short Prior Month (K) | 6280 |
| Stock Financials | |
|---|---|
| EPS | -1.800 |
| Book Value (p.s.) | 3.810 |
| Profit Margin | |
| Operating Margin | -360.98 |
| Return on Assets (ttm) | -24.6 |
| Return on Equity (ttm) | -42.8 |
| Qtrly Rev. Growth | 147.5 |
| Gross Profit (p.s.) | -1.113 |
| Sales Per Share | 0.483 |
| EBITDA (p.s.) | -1.739 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -61.89 |
| Levered Free Cash Flow (M) | -26.80 |
| Stock Valuation | |
|---|---|
| PE Ratio | -6.39 |
| PEG Ratio | -0.06 |
| Price to Book value | 3.02 |
| Price to Sales | 23.81 |
| Price to Cash Flow | -9.96 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
